Epidemiology, Staging, and Management of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index; 21 of the 61 sources its claims cite were checked for support.
Abstract
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the global proportion). Incidence has risen by 126% globally and over 40% in the US since 1990, while global mortality has risen by 94% and US mortality has fallen by 18%. The 5 year survival in the US has more than doubled over the past decades with the introduction of new targeted therapies and transplant techniques. Risk factors for MM include age (average age of diagnosis is 69), race (African Americans are over double as likely to be diagnosed), sex (men are at a 1.5× risk), and family history. Diagnosis includes serum or urine electrophoresis and free light-chain assay but requires bone marrow biopsy. It is distinguished from smoldering myeloma and monoclonal gammopathy of undetermined significance by a high (>3 g/dL) level of M-protein (monoclonal light chains) and the presence of CRAB (Hypercalcemia, Renal failure, Anemia, Bone pain) symptoms, which include hypercalcemia, renal failure, anemia, and bone pain, suggesting an end-organ damage. International staging system staging involves beta 2 microglobulin and albumin levels, while the revised system considers prognostic factors such as lactate dehydrogenase levels and chromosomal abnormalities. Front-line management includes induction regimen, maintenance therapy and hematopoietic cell transplantation for eligible patients and bisphosphonates or bone-stimulating agents for the prevention of skeletal events. Treatment for relapsed disease includes newly approved monoclonal antibodies like the CD38-targeting daratumumab, proteasome inhibitors, immunomodulating agents, and investigational therapies such as B cell maturation antigen Chimeric antigen receptor T cells.
Overview
CoChat Summary
## TL;DR
This 2021 review summarizes the epidemiology, staging, diagnosis, and management of multiple myeloma, emphasizing that incidence has risen while survival has improved with newer therapies and transplant techniques. It also highlights the major risk groups, current staging systems, and common first-line and relapsed-disease treatment approaches.
## Key findings
- Global MM burden was estimated at 160,000 cases in 2018 and 106,000 deaths in 2018; MM accounted for 0.9% of all cancer diagnoses and 1.1% of all cancer deaths.
- From 1990 to 2016, global incidence increased by 126% and global deaths increased by 94%; in the US, incidence rose by 143% since 1975, while mortality fell and 5-year survival increased from 23.7% in 1976 to 53.9% in 2016.
- Risk is higher in older adults (median diagnosis age 69 in the US), men (about 1.5× higher risk globally), and African Americans (incidence 16.5/100,000 in African American men and 12.0/100,000 in African American women, versus 8.2 and 5.0 in Caucasians).
- In an international clinical trial with 3,060 participants, 5-year survival by revised ISS stage was 82% for stage I, 62% for stage II, and 40% for stage III.
## Methods
- Narrative review article describing the “latest review” of MM; the paper states that an extensive literature search was done.
- Synthesizes epidemiologic data (e.g., GLOBOCAN, SEER), staging systems (ISS, DSS, revised ISS), diagnostic criteria, and treatment evidence from cited trials and studies.
- Main analysis is descriptive and integrative rather than experimental, comparing published incidence, mortality, risk-factor, staging, and treatment results.
## Limitations
- The paper does not report a systematic review method, search strategy, or inclusion/exclusion criteria; this is evident from the text (descriptive review), not stated as a limitation by the authors.
- The evidence base is largely observational and from cited studies/trials across different settings, so direct causal inference is limited; this is evident from the text.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Map showing the estimated age-standardized incidence rates per 100,000 (world) in 2018 of multiple myeloma (MM) for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/53cda705514b4aeea933ce5143d2fbf3/epidemiology-staging-and-management-of-multiple-myeloma-figure-1.jpg)
![Figure 2 Map showing the estimated age-standardized mortality rates per 100,000 (world) in 2018 of multiple myeloma for both sexes and all ages. Created with mapchart.net. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/0a44533b89b8450397215c10f72e1fcc/epidemiology-staging-and-management-of-multiple-myeloma-figure-2.jpg)
![Figure 3 Graph showing the estimated cumulative risk of incidence in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2. Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/525138bbaf0842a7aaa427b870ecd122/epidemiology-staging-and-management-of-multiple-myeloma-figure-3.jpg)
![Figure 4 Graph showing the estimated number of prevalent cases (5 year) as a population in 2018 of multiple myeloma for both sexes, ages 0–74. Created with Tableau 2019.2 Data obtained from GLOBOCAN 2018 [7].](https://figures.cochat.ai/paper-figures/6e96994452ec4de28c61f038e43ff651/epidemiology-staging-and-management-of-multiple-myeloma-figure-4.jpg)
![Figure 5 Bar chart showing the 5 year age-adjusted mortality rates from 2013–2017 by age for the United States. Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/82c4eb6e362047998968d2004b611456/epidemiology-staging-and-management-of-multiple-myeloma-figure-5.jpg)
![Figure 6 Bar chart showing the United States’ 5-year age-adjusted mortality rates from 2013–2017 for all races (including Hispanics). Created with Tableau 2019.2. Data source: SEER*Explorer [11].](https://figures.cochat.ai/paper-figures/b8ccac5b620b49deb4385d0716c909bd/epidemiology-staging-and-management-of-multiple-myeloma-figure-6.jpg)

Verification
Claims the paper makes
15 Valid · 12 Not valid · 29 Not checked · 10 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“KRd instead of VRd can be used as initial therapy in patients with t(4;14), t(14;16), t(14;20), and those with ≥2 high-risk abnormalities based on the results of phase 2 studies suggesting higher complete response (CR) rates and minimal residual disease negativity rates compared with historical results using VRd [28,30,31].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Disputedcites [28] Rajkumar, 2011, Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management, Am. J. Hematol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Not checked yetcites [30] Rajkumar, 2010, Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management, Am. J. Hematol. source
Checked before — its earlier verdict is held back until a new check runs.
- Not checked — no full text of the sourcecites [31] Sheng, 2017, Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials, Eur. J. Haematol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Suggested underlying factors include discrepancies in health-risk behaviors, such as smoking and alcohol consumption, and higher rates of obesity among men, though none of these risk factors have been proven in MM [9].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 2. Epidemiology > 2.3. Risk Factors
What the sources say
- Partly supportedcites [9] Cowan, 2018, Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016, JAMA Oncol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says there is a “lack of known strong risk factors for myeloma,” which supports the claim’s general caution. It does not assess smoking, alcohol consumption, or obesity individually, or identify them as explanations for higher rates among men. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.2. Staging
What the sources say
- Supportedcites [23] Palumbo, 2015, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol. source
The Introduction describes an ISS marker as reflecting tumour mass and identifies chromosomal abnormalities as biological features of multiple myeloma. The Discussion states that R-ISS combines ISS staging, chromosomal abnormalities and serum LDH, supporting the paraphrase. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Could not verifycites [33] Chim, 2018, Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond, Leukemia sourceExperimental — accuracy not yet measured
The 'Role of salvage ASCT' section discusses re-induction before a second transplant, and the 'Proposed treatment algorithm' section prefers triplets for relapsed myeloma. Neither addresses a typical 3–4-month triplet regimen before stem-cell collection to reduce tumor cells in the bone marrow; searches for that timing and purpose found no supporting passage. Page numbers were unavailable in our copy. (LLM, conf=0.76)
- Partly supportedcites [34] Laubach, 2016, Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group, Leukemia sourceExperimental — accuracy not yet measured
Our copy supports the general idea that transplant-bound relapsed patients are treated with multi-drug regimens before harvest: 'General management' states that patients with high-risk/aggressive disease 'are generally treated with highly active three-or four-drug combinations to achieve maximal response' and that responders 'can then be considered for ASCT', and 'AUTOLOGOUS STEM CELL TRANSPLANTATION' notes that 'mobilization after reinduction using various mobilization regimen... is feasible' when a new stem cell collection is needed. However, no passage in our copy specifies a 3-4 month duration of pre-harvest therapy, nor does it state that the purpose of giving it before collection is to reduce tumour cell numbers in the bone marrow; the paper frames the three-drug approach as achieving maximal response in high-risk disease and explicitly leaves one- versus two- versus three-drug choice unsettled for indolent relapse. The quantitative and rationale components of the claim are therefore not attributable to this source. (LLM, conf=0.68)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low-dose dexamethasone (i.e., once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
§ Epidemiology, Staging, and Management of Multiple Myeloma > 3. Diagnosis, Staging, and Grading > 3.3. Management
What the sources say
- Partly supportedcites [48] Rajkumar, 2010, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial, Lancet Oncol. sourceExperimental — accuracy not yet measured
The Methods (Procedures; page unavailable) specify 40 mg dexamethasone once weekly in the low-dose arm. The Results and Discussion report less toxicity and no worse progression or survival outcomes with low-dose treatment, but the Results also find a significantly lower response rate after four cycles (68.3% versus 79%). Thus, “without compromising efficacy” is too broad, and the evidence is limited to treatment with lenalidomide in newly diagnosed myeloma. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
15 more claims · 1 with their cited sources checked
Create a free account to see all 66 claims and to verify the 18 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple myeloma affects men more than women (3:2 ratio). 5,6”
From Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2024) · cites this paper as [5]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 3×
“5 mg/L, and Stage II for all those in between [19].”
BackgroundInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210 · cited 1×
“The revised international staging system (RISS) combines elements of tumor burden (ISS) and disease biology [23].”
MethodBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · cited 1×
“Albeit weak, there is data suggesting that use of a proteasome inhibitor may abrogate the prognostic impact of at least some of these high-risk genetic markers [32].”
BackgroundDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a re ceptor highly expr sed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
BackgroundRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 1×
“, once weekly 40 mg dose) is associated with less dexamethasone-related toxicity than more intensive dosing scheme without compromising efficacy [48].”
BackgroundMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · cited 1×
“, bortezomib, lenalidomide, dexamethasone) improved response rates, depth of response, progression-free survival, and overall survival compared with the then approved front-line regimen Rd (lenalidomide, dexamethasone) making a three-drug regimen the main stay of initial therapy for most patients with MM [25].”
Background
Research works printed but not linked: 3
- Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review 1975–2016.
- Vakiti, A., Padala, S.A., and Mewawalla, P. (2020, May 07). Myeloma Kidney, Available online: https://www.ncbi.nlm.nih.gov/books/NBK499952/.
- Vakiti, A., and Mewawalla, P. (2020, May 07). Malignancy-Related Hypercalcemia, Available online: https://www.ncbi.nlm.nih.gov/books/NBK482423/.
Cited by
Items 101–200 of 331
Nightingale, B., Decker, M., Ryan, R., Kaczmarczyk, K., Jandir, P., Waykole, T., ASHKAR, R., Harmon, G., Mathur, A., & Levitt, M. (2024) · World Journal of Oncology · doi:10.14740/wjon1780 · Cited by 10
Metabolomic biomarkers of multiple myeloma: A systematic review
Varzieva, V. G., Mesonzhnik, N. V., Ilgisonis, I. S., Belenkov, Y. N., Kozhevnikova, M. V., & Appolonova, S. A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189151 · Cited by 8
China's potential role in humanitarian assistance
Binder, A., & Conrad, B. (2009) · Cited by 9
Bertelsen, L. D., Nielsen, L. H., Christensen, H. S., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13904 · Cited by 6
“Knowledge of aetiology may pave the way for prevention and thereby reducing the incidence of MM in the future.(1,2) The aetiology of MM is largely unknown, but risk factors as older age, positive family history, male sex, Afro-American ethnicity, and some polygenetic factors are acknowledged; however, the exact causal…”
BackgroundResultInfluentialMurugappan, M. N., King‐Kallimanis, B. L., Bhatnagar, V., Kanapuru, B., Farley, J. F., Seifert, R. D., Stenehjem, D. D., Chen, T., Horodniceanu, E. G., & Kluetz, P. G. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03390-5 · Cited by 11
“MM is a hematologic malignancy of plasma cells, resulting in hypercalcemia, bone disease, anemia, and renal dysfunction [34].”
BackgroundRole of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics?
Michalska, A., Rogowska, A., Kwiatkowska-Miernik, A., Sklinda, K., Mruk, B., Hus, I., & Walecki, J. M. (2024) · Cancers · doi:10.3390/cancers16234099 · Cited by 8
Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma
Kwon, S., Park, H. Y., Byun, J. M., Shin, D., Koh, Y., Hong, J., Kim, I., & Yoon, S. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06372-4 · Cited by 6
Zayad, A., Magee, G., Mansour, R. A., Chang, M., Ahmed, N., Mushtaq, M. U., Paul, B. A., Green, K. M., Davis, J. A., Skikne, B., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.017 · Cited by 6
Zijlstra, H., Velde, J. P. T., Striano, B. M., Groot, O. Q., Groot, T. M., Raje, N. S., Patel, C. G., Husseini, J. S., Delawi, D., Kempen, D. H. R., et al. (2024) · Global Spine Journal · doi:10.1177/21925682241260651 · Cited by 5
“1,2 It is a malignant disease characterized by monoclonal plasma cell proliferation in the bone marrow.”
Song, Y., Zhang, H., Geng, J., Chen, H., Yang, B., & Lu, X.-C. (2024) · Scientific Reports · doi:10.1038/s41598-024-66367-5 · Cited by 7
Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors—A Literature Review
Halmágyi, S.-R., Ungureanu, L., Trufin, I. I., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154501 · Cited by 5
“Multiple myeloma (MM) is a plasma cell neoplasm with an increasing incidence in developed countries, albeit with improved survival in the last decades [121].”
BackgroundCicala, G., Russo, G., Santoro, V., Franchina, T., Silvestris, N., Santarpía, M., Spina, E., & Barbieri, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17101266 · Cited by 5
“Over 60% of MM diagnoses in the US are made in patients aged 65 years and older [26].”
BackgroundCarvalho, L. V. D. N., de Assis, R. A., Montenegro, C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413499 · Cited by 5
Detection of early relapse in multiple myeloma patients
Růžičková, T., Vlachová, M., Pečínka, L., Brychtová, M., Večeřa, M., Radová, L., Ševčíková, S., Jarošová, M., Havel, J., Pour, L., et al. (2025) · Cell Division · doi:10.1186/s13008-025-00143-3 · Cited by 9
“It is characterized by the uncontrolled proliferation of malignant plasma cells (PCs) and excessive secretion of monoclonal immunoglobulin (Ig) [2].”
Gatopoulou, X., Iraqi, W., Morgan, K., Helme, K., Spain, V. A., Redfearn, J., & Gardiner, B. (2022) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s367458 · Cited by 8
“Less than one-fourth of NDMM patients were employed at the time of the MM diagnosis (mean age at diagnosis of 69 in our study), as could reasonably be expected for a disease of patients of advanced age (our data are in line with other findings showing an average diagnosis age of 69).(43) The small share of working pat…”
BackgroundNicol, J. L., Cunningham, B. J., Woodrow, C., Adlard, K. N., Papinczak, Z. E., Spence, R. R., Boytar, A. N., Mollee, P. N., Weber, N., Nicol, A. J., et al. (2023) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003267 · Cited by 6
Chromothripsis in hematologic malignancies
Lagunas‐Rangel, F. A. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104172 · Cited by 8
Rheological properties of blood in multiple myeloma patients
Ptaszek, B., Podsiadło, S., Jandziś, Z., Teległów, A., Piotrowska, A., Jurczyszyn, A. J., & Czerwińska‐Ledwig, O. (2024) · Scientific Reports · doi:10.1038/s41598-024-54947-4 · Cited by 7
Rujirachaivej, P., Siriboonpiputtana, T., Choomee, K., Supimon, K., Sangsuwannukul, T., Songprakhon, P., Natungnuy, K., Luangwattananun, P., Yuti, P., Junking, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05923-z · Cited by 8
“Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the clonal expansion of dysfunctional plasma cells in the bone marrow, resulting in approximately 106,000 deaths annually worldwide [1, 2].”
Advances in the study of CCT3 in malignant tumors: A review
Bai, Y.-F., Shi, X., Zhang, M.-L., Gu, J., Bai, T.-L., & Bai, Y.-B. (2025) · Medicine · doi:10.1097/md.0000000000041069 · Cited by 5
Zhang, W., Chen, X., Wang, Z., Wang, Q., Feng, J., Wang, D., Wang, Z., Tang, J., Qing, S., & Zhang, Y. (2024) · Hematology · doi:10.1080/16078454.2024.2335421 · Cited by 4
Association between CTX-1 and Fibulin-1 Serum Levels with Pathogenesis of Multiple Myeloma Cancer
Al-Janabi, A. M. A. A., Momeni, H. R., & Al-Harbi, H. J. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.5.1599 · Cited by 4
“Attention reduces the incidence of MM. Population [2].”
BackgroundMiao, X., Wang, Z., Wang, H., Zeng, X., Wang, J., Luo, B., Yang, Y., Yang, J., & Zhao, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1609692 · Cited by 4
“From 1990 to 2016, the global incidence of MM increased by 126%, with an estimated 160,000 cases of MM worldwide as of 2018, of which approximately 90,000 were in men and 70,000 in women (10).”
İpek, Y., Karademir, N., Yilmazer, O., & Yılmaz, G. (2023) · Current Oncology · doi:10.3390/curroncol30060423 · Cited by 5
“Multiple myeloma (MM) is a hematological malignancy of plasma cells, which is characterized by monoclonal antibodies, which is particularly common in elderly patients [1].”
BackgroundChoi, S., Kim, E., Jung, J., Park, S., Min, C., & Han, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-52720-1 · Cited by 6
Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature
Li, J., Wang, C., & Cheng, C. (2024) · International Journal of Cancer · doi:10.1002/ijc.35057 · Cited by 4
Zhang, F., Chen, X.-L., Wang, H., Guo, T., Yao, J., Jiang, Z.-S., & Pei, Q. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01937-0 · Cited by 5
“The number of MM patients is increasing worldwide [2].”
BackgroundMultiple myeloma survival in New South Wales, Australia, by treatment era to 2020
Feletto, E., Luo, Q., Kelly, A., Weber, M. F., Goldsbury, D. E., Barron, K., Canfell, K., & Yu, X. Q. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0177 · Cited by 4
Hershkovich, O., Sakhnini, M., Barkay, G., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12681-0 · Cited by 4
“The published expected 5-year survival of multiple myeloma patients in our cohort’s age group is around 50% [32, 33].”
BackgroundEffect of adipose tissue on the development of multiple myeloma
Stanisławowski, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10174-8 · Cited by 4
“The condition is usually identified when individuals are between 62 and 69 years old, on average [5–8].”
Practical insights into bispecific antibody therapy in multiple myeloma
Kawasaki, Y., Winger, S., Esteghamat, N., Rosenberg, A. S., & Beechinor, R. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2445145 · Cited by 8
Borsi, E., Șerban, C. L., Potre, C., Potre, O., Putnoky, S., Samfireag, M., Tudor, R., Ioniță, I., & Ioniţă, H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105444 · Cited by 5
“Recognized and relatively constant risk factors are older age, male gender and African ethnicity [2].”
BackgroundWeisel, K. C., Dimopoulos, M. A., Miguel, J. F. S., Paner, A., Engelhardt, M. M., Taylor, F. C., Lord‐Bessen, J., Yip, C., Greenwood, M., Tang, J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000843 · Cited by 5
Huang, Z.-Y., Jin, X.-Q., Liang, Q., Zhang, D.-Y., Han, H., & Wang, Z. (2023) · Medicine · doi:10.1097/md.0000000000035319 · Cited by 9
Advances in research on potential inhibitors of multiple myeloma
Tang, G., Huang, S., Luo, J., Wu, Y., Zheng, S., Tong, R., Zhong, L., & Shi, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115875 · Cited by 5
Lin, S., Gao, B., Xu, R., Shang, H., Xiong, Y., Zhou, J., Yang, Z., Jiang, C., & Yan, S. (2024) · eJHaem · doi:10.1002/jha2.890 · Cited by 5
miR‑1343‑3p inhibits autophagy by directly targeting ATG7 in multiple myeloma cells
Guo, Y., Ding, X., Dai, C., Wang, W., Chen, J., Chen, S., Yang, L., & Chen, G. (2024) · Biomedical Reports · doi:10.3892/br.2024.1873 · Cited by 5
“However, co‑transfecting cells with ATG7 siRNA and the miR‑1343‑3p inhibitor reversed these phenomena; Beclin1 protein expression was decreased and p62 protein levels increased compared with in the cells transfected with miR‑1343‑3p inhibitor alone.”
BackgroundInfluentialA comprehensive review of oncogenic Notch signaling in multiple myeloma
Roosma, J. (2024) · PeerJ · doi:10.7717/peerj.18485 · Cited by 3
PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CT
Kaya, G., Akın, S., Büyükaşık, Y., Bozkurt, M. F., Tuncel, M., & Kıratlı, P. Ö. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07624-1 · Cited by 5
“…extent of BM plasma cell infiltra - tion demonstrated a moderate positive correlation with FCH uptake, both at initial diagnosis and across the entire cohort, whereas no correlation with FDG uptake likely reflecting lower infiltration percentages or biologic heterogeneity of the disease [25 – 27 ].”
Xin, X., Fan, C., Sheng, R., Li, X. C., Zhu, X., Huang, Y., Seraji, H. R., Urazbaeva, D., Atamuratova, Z., & Ubaydullaevna, A. D. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02050-5 · Cited by 4
Atypical Presentation and Diagnosis of Multiple Myeloma: A Case Report
Kong, I., Riddell, L. W., Kohler, J. M., Nguyen, M. C., & Carraro, M. N. (2024) · Cureus · doi:10.7759/cureus.51870 · Cited by 3
Li, L., Hu, X., Nkwocha, J., Kmieciak, M., Meads, M. B., Shain, K. H., Alugubelli, R. R., Silva, A. S., Mann, H., Sudalagunta, P. R., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19796 · Cited by 5
Patel, M. N., Nina, A., Branchaud, B., Herring, K. W., Johnson, S., Scott, J. E., & LeBlanc, T. W. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08985-3 · Cited by 6
“Multiple myeloma (MM) is the second most common hematologic malignancy in the United States, [1] diagnosed in nearly 35,800 individuals and leading to nearly 12,600 deaths annually [1, 2].”
Huh, Y. J., Lee, S. Y., Kim, S., et al. (2022) · British Journal of Radiology · doi:10.1259/bjr.20220009 · Cited by 3
Al-Ani, A., Naji, A. S., Taher, Y. M., Abdulsattar, S. A., Fadhil, S. Q., Jassim, H. K., & Alwan, A. (2022) · Journal of emergency medicine, trauma & acute care · doi:10.5339/jemtac.2022.aimco.6 · Cited by 3
Zhao, W., Liu, J., Wang, L., & Wang, W. (2023) · Hematology · doi:10.1080/16078454.2023.2210907 · Cited by 3
“MM accounts for 10 − 15% of haematological malignancies, with high heterogeneity, and tends to occur in middle-aged and elderly persons [2].”
BackgroundConhecendo o Mieloma Múltiplo:
Gonçalves, M. J. P., Filho, R. D. S. V., & Peçanha, M. A. P. (2023) · Revista Científica da Faculdade de Medicina de Campos · doi:10.29184/1980-7813.rcfmc.696.vol.18.n1.2023 · Cited by 3
Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison
Khadka, S., Balaji, S., Kaur, J., Solanki, D., Kasianchyk, M., Chowdhury, H., Patel, I. K., Qasim, M., Desai, M. K., Maiyani, P., et al. (2023) · Cureus · doi:10.7759/cureus.47319 · Cited by 2
“This is likely because of the complications associated with this disease and the medications used for treatment, which require advanced treatment like plasmapheresis, dialysis, multiple blood transfusions, and the need for specialists [25].”
BackgroundBerenson, J. R., Limon, A., Rice, S., Safaie, T., Boccia, R. V., Yang, H., Moezi, M. M., Lim, S. W., Schwartz, G. K., Eshaghian, S., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01049-w · Cited by 3
“Multiple myeloma (MM) is a malignant neoplasm of terminally differentiated plasma cells within the bone marrow (BM) and accounts for 10% of all hematological malignancies as well as roughly 2% of all new cancer cases and related deaths [1, 2].”
Disparities in Multiple Myeloma Mortality Rate Trends by Demographic Status in the USA
Doddi, S., & RASHID, M. H. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10322 · Cited by 3
Zhao, X., Ji, J., Li, Y., et al. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2336 · Cited by 3
Yohay, S., Oloyede, T., Kim, S., Fang, X., Dhakal, B., Aijaz, A., Mohan, M., Narra, R. K., Pasquini, M. C., D’Souza, A., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19811 · Cited by 5
Wu, Q., & Xu, J. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06347-5 · Cited by 3
“The body of literature on MM is extensive, with substan - tial research focused on its pathogenesis, epidemiology, and response to various treatments [13 – 17].”
Kortüm, K. M., Theurich, S., Farrell, J. J., Jackson, G., Cook, G., Cappelleri, J. C., Ashman, O., Neff-Baro, S., Gauthier, A., Jewiti-Rigondza, K., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14724-6 · Cited by 5
“MM is a globally prevalent hematological cancer, representing 1% of all cancer diagnoses, making it the second most common blood cancer with a median overall survival (OS) of 6 years after diagnosis [3–5].”
Chromosome Territories in Hematological Malignancies
de Lima, M. F., Lisboa, M. D. O., Terceiro, L. E. L., Pozzo, A. R., & Mai, S. (2022) · Cells · doi:10.3390/cells11081368 · Cited by 8
Diedrich, J. D., Cole, C. E., Pianko, M. J., Colacino, J. A., & Bernard, J. J. (2023) · Cancers · doi:10.3390/cancers15215255 · Cited by 2
Oral manifestations of multiple myeloma – A systematic review
Krishnan, P., Narayan, M., Divya, B., et al. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100485 · Cited by 2
Orbital Myeloma and Plasmacytoma: An Australian Study
Xiong, J., Tong, J. Y., Hyer, J. N., O’Donnell, B., Selva, D. N., Hardy, T. G., McNab, A. A., Sullivan, T. J., Taylor, S. F., Figueira, E. C., et al. (2024) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000002777 · Cited by 2
Zhang, Y., Su, Q., Yu, J., & Sun, X. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1554485 · Cited by 6
“This finding was consistent with previous research that had identified gender-specific variability in disease manifestation (11, 12).”
Danis, R., Bujarski, S. E., Yashar, D., Dosso, A. D., Moore, J., Mettias, S., & Berenson, J. R. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107677 · Cited by 3
The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies
Konieczny, K., Eighmy, W., Rux, E., et al. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251347240 · Cited by 2
Zerunian, M., Masci, B., Pugliese, D., Nardacci, S., Polici, M., Pucciarelli, F., Santis, D. D., Caruso, D., Verde, G. L., & Laghi, A. (2025) · La radiologia medica · doi:10.1007/s11547-025-02026-7 · Cited by 2
“When MM is suspected, the diagnosis includes urine or serum electrophoresis and free light chain electrophoresis; the definitive diagnosis is obtained with bone marrow biopsy and the disease is defined when greater than 10% of clonal plasma cells are found [2].”
Renal Failure Due to Multiple Myeloma
Shaik, A., & Oroszi, T. L. (2025) · Open Journal of Nephrology · doi:10.4236/ojneph.2025.152023 · Cited by 3
Solovev, M. V., Менделеева, Л. П., Soloveva, M. V., Samoylova, O. S., Davydkin, I. L., Гриценко, Т. А., Kaplanov, K. D., Kaporskaya, T. S., Shelekhova, T. V., Volodicheva, E. M., et al. (2026) · MD-Onco · doi:10.17650/2782-3202-2026-6-1-62-80 · Cited by 2
Recent Updates on Multiple Myeloma
Al-Anazi, K. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100849 · Cited by 2
Malise, T. T. A., Nweke, E. E., Takundwa, M. M., Fru, P., & Raj, D. B. T. G. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_775 · Cited by 2
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma
Liu, Y., Li, B., Chen, X., Xiong, H., & Huang, C. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2316090 · Cited by 2
“…thalido-mide, lenalidomide (LEN), and pomalidomide (POM) have been progressively used in the management of MM in China throughout the past decade [10], and recently CRBN E3 ligase-modulating drugs (CELMoD) have conducted many clinical trials in myeloma [11–13], showing strong immunomodulatory…”
BackgroundMazurek, M., Szudy‐Szczyrek, A., Homa‐Mlak, I., Hus, M., Malecka-Massalska, T. J., & Mlak, R. (2024) · Cancers · doi:10.3390/cancers16071263 · Cited by 2
“MM most often affects patients over 65 years of age and is 1.5 times more likely to affect men [4,5].”
BackgroundInfluentialJimmy, J., Jha, V., Ajeesh, G., Aryalakshmi, B., Sidharthan, N., & Unni, M. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_210_23 · Cited by 3
Geraldes, C., Neves, M., Bergantim, R., da Silva, C. C., & da Costa, F. L. (2024) · Cancer Reports · doi:10.1002/cnr2.70027 · Cited by 2
Mandavkar, A. A., Padakanti, S. S. N., Gupta, S., Akram, S., Jaffar, N., Chauhan, J., Allu, L. R., Saini, P., Nasrallah, J., Omar, M. A., et al. (2025) · Human Antibodies · doi:10.1177/10932607241301699 · Cited by 2
Knowledge, attitude and practice towards multiple myeloma among medical staff in Enshi Region
Zou, L., Li, J., Xiang, H., Tan, J. H., & Zeng, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-88079-0 · Cited by 3
Cherkaoui, S., Penickova, S., & COTTON, F. J. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110892 · Cited by 4
Zilu, M., Zheng, H., Li, Y., Bai, J., Zhang, L., & Li, L. (2025) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2025.101202 · Cited by 3
Sharkawi, M. M. Z., Amin, N. H., Mohamed, N. R., Zaki, S. S., & Hemeda, L. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-15078-6 · Cited by 2
Forbat, L., Sedgley, T., & Bellussi, L. (2023) · European Journal of Cancer Care · doi:10.1155/2023/6292479 · Cited by 3
“Since the median age of diagnosis is 69 years [4], many patients are of working age.”
Piorno, F. J. C., González-García, E., Méndez-Gallego, A., Torres-Varona, J., Moreira, V. G., Sordo‐Bahamonde, C., Alberdi-García, C., Astobieta-Madariaga, E., Mateos, M., & Gonzalez, S. R. (2022) · Advances in Hematology · doi:10.1155/2022/4282226 · Cited by 4
“Measurement of GFR using inulin infusion or radiotracers is one of the most accurate methods to evaluate the renal function, but it is time-consuming, expensive, and not available in most hospitals [5].”
BackgroundMethodManier, S., Dimopoulos, M. A., Hulin, C., Leleu, X. P., Delforge, M., Weisel, K. C., Mouro, J. L., Costa, B. A., Sturniolo, M., & Facon, T. T. F. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.06.002 · Cited by 2
Optimization of treatment of patients with plasma cell myeloma with high cytogenetic risk in Poland
Giannopoulos, K., Jamroziak, K., Wróbel, T., & Dytfeld, D. (2022) · Hematologia · doi:10.5603/hcp.a2022.0007 · Cited by 3
“The progressive infiltration of pathological plasma cells may cause frequent infections, anaemia, renal failure, peripheral neuropathy and venous thromboembolism [4, 5].”
Chen, L., Yi, K., Lan, H., Zhang, Y., Jin, S., Mou, X., Xian, H., Fu, W., & Li, R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-394 · Cited by 2
Iqbal, R., Rehman, S., Sukaina, M., Ullah, H., Hameed, M., & Chattha, U. (2023) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.8068 · Cited by 1
Tyczyńska, A., & Zaucha, J. M. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/168685 · Cited by 3
Mehrzad, V., Mehdizadeh, M., Parkhideh, S., et al. (2023) · International Journal of Cancer Management · doi:10.5812/ijcm-137802 · Cited by 1
“It mainly affects males in their 7th-8th decades of life (1).”
BackgroundA study to identify novel biomarkers associated with multiple myeloma
Kalarani, I. B., & Veerabathiran, R. (2023) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-5-134-144 · Cited by 1
Kazgı, M. A., Bayram, E., Köşeci, T., Mete, B., Toyran, T., Ergin, M., & Kara, İ. O. (2024) · Biomedicines · doi:10.3390/biomedicines12051014 · Cited by 2
“MM accounts for 1% of all cancers and approximately 10% of haematological cancers [1,2].”
BackgroundKurek, M., Tatara, T., Świtalski, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-82301-1 · Cited by 1
Bilancia, M., Solimando, A. G., Manca, F., Vacca, A., & Ria, R. (2025) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2025.108130 · Cited by 1
Ripa, M., Schipa, C., Aceto, P., & Shah, N. A. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03467-9 · Cited by 2
“…and epigenetic changes lead to an uncontrolled proliferation of plasma cells that impedes the normal course of blood cells, leading to anemia and an abnormal increase of monoclonal immunoglobulin that infiltrates the vital organ, ultimately leading to end-organ damage such as renal failure [25].”
Jia, Z., & Lu, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-96565-8 · Cited by 3
“When these abnormal monoclonal plasma cells are targeted and die under the action of chemotherapy drugs, the production of M-protein correspondingly decreases 13,14 .”
Gordan, L., Medhekar, R., Fu, A. Z., Shokoohi, M., Ramirez, A. O., Bonar, N., Ngoc, N. B., Spence, M., McTavish, R. K., Disher, T. C., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70061 · Cited by 1
Wu, D., Wang, F., Yang, X., Yang, B., Chen, J., Cheng, J., Wei, B., Yuan, X., Tian, T., Liu, Z., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02304-w · Cited by 1
“Multiple myeloma (MM) is a heterogeneous genetic disease characterized by the presence of abnormal clonal plasma cells in the bone marrow [1, 2].”
Zayad, A., Ahmed, N., Mahmoudjafari, Z., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.019 · Cited by 1
McCalmont, A., Darwish, N., Donaldson, D. M., & Meguid, E. M. A. (2025) · eJHaem · doi:10.1002/jha2.70071 · Cited by 1
Patterns of multimorbidity in older adults with multiple myeloma: An analysis of SEER-Medicare
Oyinbo, A. G., Tisminetzky, M. S., Baek, J., Castañeda‐Avila, M. A., DuMontier, C., Ramanathan, M., Lapane, K. L., & Epstein, M. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330331 · Cited by 1
“Our findings are generalizable to adults aged ≥65 years with newly diagnosed multiple myeloma in the US with fee-for-service Medicare, an age group that makes up two-thirds [5] of all newly diagnosed cases.”
Sharma, N. S., Nataraj, K. S., & Choudhary, B. (2025) · Medical Oncology · doi:10.1007/s12032-025-03032-5 · Cited by 1
“Although high-risk cytogenetic testing is recommended, it remains uncommon in many developing countries [3, 7, 8].”
Linkou, M. V., Veyalkin, I. V., Козич, Ж. М., Yauseichyk, K. S., & Усова, Н. Н. (2025) · Medical and Biological Problems of Life Activity · doi:10.58708/2074-2088.2025-3(35)-19-26 · Cited by 1
HERV-K Envelope Induce a Humoral Response in Non-Hodgkin Lymphoma Patients
Cossu, I., Ruberto, S., Filippi, E., Simula, E. R., Noli, M., Mottula, A., Fozza, C., & Sechi, L. A. (2025) · Current Microbiology · doi:10.1007/s00284-025-04511-8 · Cited by 1
“Multiple myeloma (MM) is marked by cycles of remission and relapse and is driven by the uncontrolled proliferation of monoclonal antibody-producing plasma cells [10–12].”
Yi, B., Gao, Y., Huang, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1650510 · Cited by 1
“MM is a malignant hematologic tumor originating from plasma cells, characterized by typical clinical manifestations such as hypercalcemia, anemia, renal impairment, and osteolytic lesions, collectively referred to as CRAB symptoms (26, 27).”
Pons-Fuster, E., Riquelme‐Pérez, A., Samkohvalov, V. S., Gonzalez-Ponce, C. M., Fernández-Ávila, J. J., Ramón-Martínez, A., Moreno-Belmonte, M. J., Cabañas, V., Pascual-Figal, D. A., Díaz-Carrasco, M. S., et al. (2026) · Cancers · doi:10.3390/cancers18121924 · Cited by 1
“A major limitation of the current model is its reliance on baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is frequently elevated in cancer patients due to age, renal dysfunction, or comorbidities [15,16].”
Metadata
- Authors
- Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H.
- Affiliations
- Augusta University (US)
- Allegheny Health Network (US)
- Sovah Health Martinsville (US)
- Corresponding author
- Padala, Sandeep Anand
- ORCID
- Venue
- Medical Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-20
- Volume
- 9
- Issue
- 1
- Pages
- 3
- ISSN
- 2076-3271 (ISSN-L)
- PMC
- PMC7838784
- OpenAlex
- W3125352349
- Semantic Scholar
- f98f43b63e68b1a4fa37ed1682b10b64d590a291
- Cited by
- 332
- References
- 56
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 87 · 2023: 66 · 2022: 38 · 2021: 5
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medical Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, incidence and mortality trends, risk factors, M protein, International Staging System, beta2-microglobulin, lactate dehydrogenase, chromosomal abnormalities, hematopoietic stem cell transplantation, bisphosphonates, skeletal-related events, relapsed multiple myeloma, daratumumab, proteasome inhibitors, immunomodulating agents, CAR T-cell therapy, BCMA, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma
- MeSH terms
- Immunomodulating Agents, Anemia, Humans, Hypercalcemia, Multiple Myeloma, Pain, Paraproteinemias, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.